Holen Sie sich die Stockscreener-App
47.75
0.99%
-0.46
Handel nachbörslich:
48.70
0.95
+1.99%
Schlusskurs vom Vortag:
$48.21
Offen:
$48.44
24-Stunden-Volumen:
370.66K
Relative Volume:
0.53
Marktkapitalisierung:
$2.77B
Einnahmen:
$718.95M
Nettoeinkommen (Verlust:
$-38.55M
KGV:
-69.82
EPS:
-0.6839
Netto-Cashflow:
$45.99M
1W Leistung:
+0.24%
1M Leistung:
-4.07%
6M Leistung:
+3.19%
1J Leistung:
+48.71%
1-Tages-Spanne:
$47.42
$48.68
1-Wochen-Bereich:
$47.42
$49.83
52-Wochen-Spanne:
$30.83
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
47.81 | 2.80B | 718.95M | -38.55M | 45.99M | -0.6839 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate - Yahoo Finance
Why Supernus Pharmaceuticals Shares Surged - AOL.com
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Supernus Reaches Milestone, Triggers Contingent Value Rights Payment - TipRanks
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone. - Bitget
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Three Growth Stocks Under Pressure: Supernus, RGA, and Black Stone MineralsNews and Statistics - IndexBox
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call HighlightsNews and Statistics - IndexBox
Trading Systems Reacting to (SUPN) Volatility - Stock Traders Daily
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
SUPN Technical Analysis & Stock Price Forecast - Intellectia AI
Supernus Pharmaceuticals reports strong demand rebound after resolving supply constraints in March 2026 - Pluang
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed? - Sahm
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Supernus (SUPN) Q1 2026 Earnings Transcript - AOL.com
Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative - Sahm
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance - Sahm
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - The Globe and Mail
Supernus Pharmaceuticals Reports Strong Q1 2026 Results with 56% Revenue Growth - IndexBox
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference - The Manila Times
Supernus offers May 12 webcast as CEO joins Bank of America event - Stock Titan
Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)? - Yahoo Finance
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55 - Moomoo
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2026 Earnings Call Transcript - Insider Monkey
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges - The Globe and Mail
Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN
Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Supernus Pharmaceuticals | 8-K: Supernus Announces First Quarter 2026 Financial Results - Moomoo
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Earnings call transcript: Supernus Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Canada
Supernus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Supernus: Q1 Earnings Snapshot - WKYC
Q1 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan
[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance
Supernus (NASDAQ: SUPN) posts 39% revenue growth and reaffirms 2026 outlook - Stock Titan
Supernus Announces First Quarter 2026 Financial Results - marketscreener.com
BRIEF-Supernus Pharmaceuticals Q1 Product Sales USD 150.8 Million - TradingView
Supernus faces earnings test as Onapgo launch gains traction - Investing.com
Supernus faces earnings test as Onapgo launch gains traction By Investing.com - Investing.com Canada
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):